Healthcare Industry News: neurodegenerative
News Release - January 17, 2019
Asceneuron Appoints Peter Van Vlasselaer as ChairmanSerial biotech entrepreneur joins leading small molecule tau modulation company
LAUSANNE, Switzerland and CAMBRIDGE, Ma., January 17, 2019 -- (Healthcare Sales & Marketing Network) -- Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors.
Peter Van Vlasselaer, PhD has over 20 years executive and entrepreneurial experience in the biotech industry. He was most recently the Founder, President and Chief Executive Officer of ARMO Biosciences, Inc. which shortly after its public offering (Nasdaq: ARMO) was acquired by Eli Lilly. Prior to this, he was President and Chief Executive Officer of iPierian (acquired by BMS), ARRESTO (acquired by Gilead) and AVIDIA (acquired by AMGEN). In addition to founding ARMO, Dr. Van Vlasselaer was the founder of ARRESTO, co-founder of TrueNorth (acquired by Bioverativ) and was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He currently serves on the boards of BLADE Therapeutics, Comet Therapeutics and RGENIX. Dr. Van Vlasselaer has a degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He was a Post-Doctoral Fellow in the Division of Immunology and Rheumatology at Stanford University Medical School and DNAX Research Institute. Dr. Van Vlasselaer has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.
Dirk Beher, Chief Executive Officer and Founder of Asceneuron, commented:
"We are delighted to welcome Peter Van Vlasselaer to the Board. His extensive experience in all aspects of biotechnology, drug and corporate development will be invaluable as the Company progresses its orally-bioavailable tau modifiers through clinical development. With Peter's addition to the board, our expanded US presence, and commitment to tau, Asceneuron is well positioned to revolutionize the treatment of neurodegenerative diseases."
Peter Van Vlasselaer, new Chairman of Asceneuron, added:
"There is a strong industry and scientific interest in tau approaches to Alzheimer's disease and orphan tauopathies such as progressive supranuclear palsy (PSP). I believe Asceneuron's technology represents a significant opportunity in the next generation of drugs that could potentially transform the treatment of PSP and other tau-related neurodegenerative diseases. These disorders have devastating outcomes for patients and their families. I look forward to maximising the potential of these innovative new treatments and support the Company through this important phase of growth."
Asceneuron's lead program ASN120290 is a small molecule inhibitor of the enzyme O-GlcNAcase. Based on its unique mechanism of action, ASN120290 has the potential to become a first in class treatment for progressive supranuclear palsy (PSP) and other tau-related dementias.
The company recently announced the appointment of CNS specialist Dr Thomas C. Wessel as Chief Medical Officer. A clinical trial is ongoing with ASN120290 to quantify target engagement in the human brain using positron emission tomography (PET) the results of which will guide dose selection for an efficacy trial in PSP planned for later this year.
Asceneuron is an emerging, clinical stage biotech company excelling in the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer's and Parkinson's diseases. The lead program ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Asceneuron is a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Asceneuron's lead program ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP) and was recently granted Orphan Drug Designation by the US FDA for the treatment of PSP. ASN120290 has recently completed a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers. Data from that study were presented at the Alzheimer's Association International Conference (AAIC) in Chicago July 22-26, 2018.
About Progressive Supranuclear Palsy (PSP)
PSP, also known as Steele-Richardson-Olszewski syndrome, is a rapidly progressing neurodegenerative disorder. PSP is often misdiagnosed because it is relatively rare and certain symptoms are similar to Parkinson's disease. However, PSP is much more common than previously believed. Its prevalence is about three to six people per 100,000 individuals. Symptoms generally appear in the 60s-70s but can affect people from the age of 40 onwards. There are currently no treatments available to cure this disease.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.